

Edgar Filing: INTROGEN THERAPEUTICS INC - Form 8-K

INTROGEN THERAPEUTICS INC
Form 8-K
November 13, 2003

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2003

Introgen Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	0-21291	74-2704230
----- (State or other jurisdiction of incorporation)	----- (Commission File Number)	----- (IRS Employer Identification No.)
301 Congress Avenue, Suite 1850, Austin, Texas		78701
----- (Address of principal executive offices)		----- (Zip Code)

Registrant's telephone number, including area code: (512) 708-9310

(Former name or former address, if changed since last report)

Item 7. Financial Statements and Exhibits.

(c) Exhibits.

99.1 Press Release dated November 12, 2003.

Item 12. Results of Operations and Financial Condition.

Attached hereto as Exhibit 99.1 and incorporated by reference herein is the text of the registrant's press release, dated November 12, 2003, regarding results of operations and financial condition for the registrant's third fiscal quarter ended September 30, 2003.

The information in this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 12, 2003

INTROGEN THERAPEUTICS, INC.

Edgar Filing: INTROGEN THERAPEUTICS INC - Form 8-K

/s/ James W. Albrecht, Jr.

James W. Albrecht, Jr.
Chief Financial Officer

-2-

INDEX TO EXHIBITS

Exhibit Number -----	Description of Document -----
99.1	Press Release dated November 12, 2003.